Lorbrena Approved for second- or third-line treatment of ALK-positive metastatic NSCLC

(November 8, 2018)

The US Food and Drug Administration granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on (Xalkori... Continue Reading


FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

(November 5, 2018)

On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed... Continue Reading


November Is National Lung Cancer Awareness Month

(October 23, 2018)

Treatment advances – lung cancer resources and advocacy are making the difference The month of November brings lung cancer into focus. Over the past few years great strides have been made in the treatment of non-small cell lung cancer due to the... Continue Reading


Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone

(October 15, 2018)

Penn study shows patients with treatable mutations identified by liquid biopsy also largely respond to therapy October 11, 2018 PHILADELPHIA – In one of the largest clinical studies to ever examine the impact of using a blood test to detect treatable... Continue Reading


Immune-mediated Nephritis Reported to Occur with Tecentriq®

(August 30, 2018)

Immune-mediated Nephritis Reported to Occur with Tecentriq® Enough patients have developed immune-mediated nephritis which has been biopsy-confirmed in many cases that the manufacturer of Tecentriq now considers this to be an important adverse reaction. ... Continue Reading


Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer

(July 10, 2018)

Two clinical studies highlight the importance of evaluating overall health instead of age in the management of lung cancer. In fact, younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless... Continue Reading


Precision Cancer Medicine PARP Inhibitor Promising Treatment for Small Cell Lung Cancer

(June 25, 2018)

The results of a recent study published in The Journal of Clinical Oncology suggest the first new therapeutic option for Small Cell Lung Cancer (SCLC) in many years.  The study evaluated the addition of a novel precision cancer medicine called a PARP... Continue Reading


Keytruda Trail Results Suggest Change in Management of Squamous Non-Small Cell Lung Cancer

(June 22, 2018)

An interim analysis of the phase III KEYNOTE-407 trial evaluated combined chemotherapy and immunotherapy showed a more than four-month longer median overall survival for metastatic squamous non–small-cell lung cancer (NSCLC) patients who received keytruda... Continue Reading


Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations

(June 5, 2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or... Continue Reading


Loxo-292 Promising for Lung and Other “RET Fusion” Cancers

(June 4, 2018)

On Saturday, Loxo Oncology in a presentation at the American Society of Clinical Oncology annual meeting in Chicago unveiled clinical trial data for LOXO-292, a novel precision cancer medicine targeting tumors containing a mutated protein known as RET. About... Continue Reading


Latest Lung Cancer News By Stage


General Lung Cancer

Sorry, there are no articles available for this cancer stage.

More General Lung Cancer